Regeneron Pharma (REGN) PT Raised to $761 at Baird
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads gains as SpaceX, Super Micro results improve AI appetite
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Price: $801.48 -0.74%
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Rating Summary:
30 Buy, 18 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 17 | New: 13
Join SI Premium – FREE
Baird analyst Brian Skorney raised the price target on Regeneron Pharma (NASDAQ: REGN) to $761.00 (from $742.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Regeneron Pharma (REGN) PT Raised to $980 at TD Cowen
- GE Aerospace (GE) PT Lowered to $375 at RBC Capital
- salesforce.com (CRM) PT Raised to $250 at DA Davidson on Braze Deal
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
